Introduction
Myocardial hypoxia can be caused by ischemic hypoxia with a local reduction of coronary blood flow and by systemic hypoxia with lowered levels of arterial oxygen. It is well accepted that myocardial injury is closely associated with the severity of ischemic hypoxia relevant to the clinical manifestation of ischemic heart disease. Yet myocardial injury, if any, caused by systemic hypoxia at moderate levels under chronic conditions is still controversial. This may relate to the fact that myocardial function is essentially normal in high-altitude natives, in subjects during ascent and sojourns at high altitudes, and in patients with chronic obstructive pulmonary disease (COPD). Many studies have showed that short-term hypoxia can confer cardioprotection against myocardial infarction, contractile dysfunction and ventricular arrhythmias [1] [2] [3] . However, hypoxia in the long term could have adverse effects on myocardial functions, particularly shown by the deterioration of calcium (Ca 2+ ) homeostasis in sarcoplasmic reticulum (SR) [4, 5] and by impaired Gs(alpha) and adenylyl cyclase intracellular signaling functions leading to altered myocardial responses to beta-adrenoceptor activation [6] .
Recent studies have shown that overproduction of reactive-oxygen species (ROS) is a major mechanistic cause of myocardial injury during ischemia/hypoxia-reperfusion (I/R) [7] [8] [9] . Such a robust increase in cellular ROS levels could lead to opening of mitochondrial permeability transition pore [10, 11] and impaired intracellular Ca 2+ homeostasis [12, 13] . Hence, one rationale behind pharmacologically induced cardioprotection against I/R injury was to lower the ROS level during the oxidative insult. However, it is not clear if this pharmacological strategy could be beneficial to myocardial functions under chronically hypoxic conditions.
It is well known that melatonin, as well as its metabolites are potent antioxidants [14, 15] and melatonin is a cardioprotective agent against I/R injuries [16] [17] [18] [19] [20] [21] [22] . The Abstract: Chronic hypoxia (CH) leads to the deterioration of myocardial functions with impaired calcium handling in the sarcoplasmic reticulum (SR), which may be mediated by oxidative stress. We hypothesized that administration of antioxidant melatonin would protect against cardiac and ischemia-reperfusion (I/R) injury by ameliorating SR calcium handling. Adult Sprague-Dawley rats that had received a daily injection of melatonin or vehicle were exposed to 10% oxygen for 4 wk. The heart of each rat was then dissected and perfused using a Langendorff apparatus. The ratio of heart-to-body weight, ventricular hypertrophy and hematocrit were increased in the hypoxic rats compared with the normoxic controls. Malondialdehyde levels were also increased in the heart of hypoxic rats and were lowered by the treatment of melatonin. The hearts were subjected to left coronary artery ischemia (30 min) followed by 120-min reperfusion. Lactate dehydrogenase leakage before ischemia, during I/R and infarct size of the isolated perfused hearts were significantly elevated in the vehicletreated hypoxic rats but not in the melatonin-treated rats. Spectroflurometric studies showed that resting calcium levels and I/R-induced calcium overload in the cardiomyocytes were more significantly altered in the hypoxic rats than the normoxic controls. Also, the hypoxic group had decreased levels of the SR calcium content and reduced amplitude and decay time of electrically induced calcium transients, indicating impaired contractility and SR calcium re-uptake. Moreover, there were reductions in protein expression of calcium handling proteins, markedly shown at the level of SR-Ca 2+ ATPase (SERCA) in the heart of hypoxic rats. Melatonin treatment significantly mitigated the calcium handling in the hypoxic rats by preserving SERCA expression. The results suggest that melatonin is cardioprotective against CH-induced myocardial injury by improving calcium handling in the SR of cardiomyocytes via an antioxidant mechanism. mechanistic effect of melatonin on I/R-induced myocardial infarction is commonly attributed to its antioxidant properties and its ability to scavenge free radical species [23] [24] [25] while also stimulating the synthesis of antioxidant enzymes [26] [27] [28] . Although recent studies have documented the acute effects of melatonin against myocardial I/R injury, currently there is a lack of information on the chronic effect of melatonin on myocardial functions in prolonged hypoxia (CH). In this study, we examined the hypothesis that chronic administration of melatonin can alleviate CHinduced myocardial injury in rats. Results suggested that the melatonin treatment could reduce the level of oxidative stress and mitigate SR-Ca 2+ handling in the cardiomyocytes leading to improved myocardial functions in the hypoxic rats.
Material and methods

Animals
Animal care and experimental protocol for this study were approved by the Committee on the Use of Live Animals in Teaching and Research of The University of Hong Kong. The Laboratory Animal Unit of The University of Hong Kong is fully accredited by the Association for Assessment and Accreditation for Laboratory Animal Care (AAALAC International). Male Sprague-Dawley rats weighing about 70 g at age 28 days were randomly divided into normoxic and CH groups as reported previously [4] [5] [6] . While the normoxic controls were maintained in room air, CH rats were kept in a 300-L acrylic chamber for normobaric hypoxia in the same room and had free access to water and chow. The oxygen fraction inside the chamber was kept at 10 ± 0.5%, 24 hr per day. The desired oxygen content was established by a mixture of room air and nitrogen that was regulated and monitored by an oxygen analyzer (Vacumetrics Inc., CA, USA) [29] . The rats were exposed to hypoxia for 28 days and were immediately used in the experiments. The animal room was controlled at a constant temperature (22 ± 2°C), humidity and light:dark cycle (lights on 07:00-19:00).
Drug preparation
Melatonin (Sigma, St. Louis, MO, USA) solution was prepared fresh before injection by dissolving the indoleamine in absolute ethanol and further dilution with normal saline; the final concentration of ethanol was 2%. As reported previously, melatonin in 10 mg/kg body weight [30] [31] [32] [33] or vehicle (2% ethanol in normal saline) was administered intraperitoneally each day. The rats were taken out of the chamber for 30 min for the administration.
Isolated perfused heart preparation
Rats from normoxic and CH groups (both melatonin-and vehicle-treated groups) were decapitated and the hearts were quickly removed and placed in ice-cold KrebsHenseleit (K-H) perfusion buffer before being mounted on the Langendorff apparatus for perfusion at 37°C with K-H buffer at constant pressure (100 cm of H 2 O) and equilibrated with 95% of O 2 /5% CO 2. The buffer contained (in mm) 118.0 NaCl, 4.7 KCl, 1.25 CaCl 2 , 1.2 KH 2 PO 4 , 1.2 MgSO 4 , 25.0 NaHCO 3 and 11.0 glucose. All the hearts were subjected to regional ischemia described previously [34, 35] . Briefly, a snare was formed by placing a silk suture around the left coronary artery of rat heart. The snare was pulled in order to occlude the coronary artery to produce ischemia. Reperfusion was done by releasing the snare. In this present study, the isolated rat hearts were subjected to 30 min of ischemia followed by 120 min of reperfusion which induced myocardial injury.
Measurement of the area of risk
To determine the infarct size, the coronary artery was re-occluded at the end of reperfusion and the heart was perfused with 2.5% Evans blue to delineate the area of risk. The hearts were frozen at )70°C, cut into thin slices, which were perpendicular to the septum, from the apex to the base. Then incubated in sodium phosphate buffer containing 1% (w/v) 2,3,5-triphenyl-tetrazolium chloride for 10 min in order to visualize the unstained infarct region. The infarct and the risk zone areas were determined by planimetry with software Image/J from the National Institutes of Health (Bethesda, MD). The infarct size measured was expressed as a percentage of the risk zone.
Determination of myocardial injury by lactate dehydrogenase (LDH) efflux
The effluent from each isolated perfused rat heart was collected at 15 min before regional ischemia, 5th min of reperfusion and the LDH was assayed spectrophotometrically by using a kit purchased from Sigma-Aldrich (St. Louis, MO, USA). The LDH activity measured was expressed as units per liter.
Measurement of lipid peroxidation
The lipid peroxidation was determined by using a Bioxytech Ò LPO-586Ô kit (OxisResearch, OR, USA). The reaction product was measured spectrophotometrically at 586 nm. Standard curves were constructed with 1,1,3,3-tetraethoxypropane as a standard. The level of malondialdehyde (MDA) in the heart is expressed as lM, while the MDA concentration (lM) in heart was normalized to wet tissue weight (mg) and expressed as lm/mg.
Preparation of isolated ventricular myocytes
Single ventricular myocytes were isolated from the normoxic and CH rats by using a collagenase method described previously [35, 36] . After isolation, myocytes were allowed to stabilize for at least 30 min before any experiment. 50 ) was used to represent the decay of both transients. During the measurements, the isolated fura-2-loaded cardiomyocytes from each group were incubated for 10 min with non-glucose K-H solution containing 10 mm 2-deoxyd-glucose and 10 mm sodium dithionite to induce metabolic inhibition and anoxia (MI/A). Reperfusion (MI/A-R) was followed by incubating the myocytes with normal K-H solution for further 10 min.
Measurement of [Ca
Western blotting for SERCA, RyR and NCX Isolated cardiomyocytes from normoxic and hypoxic groups were collected after collagenase digestion from whole hearts. To detect the expression of SERCA2 and RyR, SR vesicles were obtained by following procedures. Briefly, myocytes were sonicated on ice in the extraction medium containing (in mm): 15 Tris, 10 NaHCO 3 , 5 NaN 3 , 250 sucrose and 1 EDTA (pH 7.3). The homogenate were centrifuged for 10 min at 1000 g to remove cellular debris. The supernatant was further centrifuged for 35 min at 20,000 g. Then the pellet was re-suspended in a mixture of 0.6 m KCl and 0.03 m histidine (pH 7.0) and centrifuged for 35 min at 20,000 g. The final pellet was re-suspended in a mixture of 0.25 m sucrose and 0.01 m histidine (pH 7.3) and stored at )70°C. All solutions contained three proteases inhibitors: 1 mg/mL leupeptin, 1 mg/mL aprotinin and 1m m phenylmethylsulfonyl fluoride (PMSF). For the measurement of NCX, purification of plasma membrane vesicles were carried out as described above. The pellet i.e. sarcolemma-enriched fraction was dissolved in the lysis buffer (0.6 m sucrose and 10 mm imidazole-HCl, pH 7.0) and stored at )70°C. The protein concentration of the samples was quantified by the Bio-Rad protein assay method by using bovine serum albumin (BSA) for the standard curve. Sample proteins (20 lg/lane) were separated in SDS-polyacrylamide gel (10% for SERCA and NCX; 6% for RyR) and transferred electrophoretically to polyvinylidene difluoride membranes (0.2 lm pore size; Bio-Rad 1 )a t4°C in transfer buffer with glycine, Tris and 20% methanol with the Bio-Rad Trans-blot electrophoretic transfer system. After blocking with Tris-buffered saline (TBS; with Tris, NaCl and 0.2% Tween 20) containing 5% non-fat milk, the membranes were incubated overnight at 4°C with the goat anti-SERCA2a polyclonal antibody (1:400 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-RyR2 monoclonal antibody (1:3330 dilution; Affinity BioReagent, Golden, CO, USA), mouse anti-NCX1 monoclonal antibody (1:500 dilution; Abcam, Cambridge, UK) and mouse anti-b-actin monoclondal antibody (1:5000 dilution; Santa Cruz Biotechnology). The second antibody for both protein determinations was anti-goat or anti-mouse antibody conjugated to horseradish peroxidase (1:2000 dilution; Dakocytomation, Denmark A/S) in 5% non-fat milk TBS for 1 hr at room temperature. The protein bands of SERCA, RyR and NCX were detected by the chemiluminescence method (ECL Western blotting detection; Amersham Biosciences 2 ).
Statistical analysis
Values are expressed as means ± S.E.M. One-way ANOVA (TurkeyÕs multiple comparison test) was used to determine the differences among the multiple groups. The significance level was set at P < 0.05.
Results
As shown in Fig. 1 , the ratio of heart-to-body weight was increased in the CH rats (vehicle-and melatonin-treated Values are means ± S.E.M., n = 6 rats each group. *P < 0.05 and ***P < 0.001 versus normoxic group and ### P < 0.001 versus VCH group. RV, right ventricle; LV, left ventricle; SP, septum. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 groups were, respectively, 143.8% and 125% of the normoxic control). The ratio of left ventricular weight to the right ventricle and septum in the vehicle-treated hypoxic rat was increased by 10.1% of the normoxic control, but was not different between the melatonin-treated hypoxic rat and the normoxic control (Fig. 1B) . Hematocrit was increased by 17.0% and 21.2%, respectively, in the vehicleand melatonin-treated rats, comparing with the normoxic control (Fig. 1C) . Fig. 2 shows the MDA level in the cardiac tissue, representing the level of lipid peroxidation under oxidative stress. The MDA level significantly increased in the vehicle group, which was 313% of the normoxic control, but the increase was much less at 25% in the melatonin group. Before ischemia, the resting level of the LDH release from the perfused heart of the vehicle-treated hypoxic rats was significantly elevated by 38.6% of the normoxic control (Fig. 3A) . There were no differences in the resting LDH release between the melatonin-treated group and the normoxic control, suggesting that melatonin reduced the CH-induced myocardial injury. In addition, the LDH release during 5 min reperfusion after ischemia was markedly increased in the vehicle group (127% of the normoxic control) but not in the melatonin-treated group (105% of the normoxic control, Fig. 3B ). Moreover, the infarct size of the hearts in the melatonin-treated hypoxic rat (101% of the normoxic control) was significantly less than that of the vehicle group (124% of the normoxic control, Fig. 3C ). Fig. 2 . Levels of MDA in the rat heart in normoxic control, vehicletreated (VCH) and melatonin-treated (MCH) hypoxic rats. Values are means ± S.E.M., n = 6 rats each group. ***P < 0.001 versus normoxic group and ### P < 0.001 versus VCH group.
Fig. 3. Levels of LDH release (A) before 30-min ischemia, (B)
during 5-min of reperfusion and (C) the infarct size in rat hearts subjected to 30-min ischemia followed by 120-min reperfusion.
Values are means ± S.E.M., n = 6 rats in each normoxic control, vehicle-treated (VCH) and melatonin-treated (MCH) hypoxic group. *P < 0.05 versus normoxic group and # P < 0.05 VCH group. of the intracellular calcium shown by fluorescence ratio (F340/F380) recorded from the isolated ventricular myocyte before and during 10-min metabolic inhibition and anoxia (MI/A) and 10-min reperfusion (MI/A-R). Values are means ± S.E.M., n = 3-4 myocytes from three to four rats in each normoxic control, vehicle-treated (VCH) and melatonin-treated (MCH) hypoxic group. **P < 0.01 versus corresponding normoxic group; ## P < 0.01 versus corresponding VCH group; + P < 0.05 versus corresponding group before MI/A-R. Before ischemia, the resting level of cytosolic calcium in isolated cardiomyocytes was higher in the hypoxic rats treated with vehicle than those of the melatonin-treated rats and the normoxic control (Fig. 4) . Following 10 min MI/ A-R, the calcium overloading was worsened in the vehicle group (110% of the resting level), but was significantly less in the melatonin group (106% of the resting level), compared with that of the normoxic control (107% of the resting level). [37, 38] . Before ischemia, the C[Ca 2+ ] i amplitude was significantly lowered in the vehicle-treated hypoxic rats by 36% of the normoxic control (Fig. 5A ). Yet, the reduced SR-Ca 2+ content was much less in the melatonin-treated rats, which was by 16% of the normoxic control. Following MI/A-R, the amplitudes were decreased further by 25% and 28% of the levels before MI/A-R, respectively in the normoxic control and vehicle-treated hypoxic rats. However, the decrease was less in the hypoxic rats treated with melatonin (23% of the level before MI/A-R), reflecting that SR-Ca 2+ content was better maintenance in the cardiomyocyte of CH rats with the melatonin treatment. Furthermore, the values of T 50 of C[Ca 2+ ] i (Fig. 5B ) which mainly reflects sarcolemmal NCX activity during caffeine-induced RyR release of Ca 2+ from SR [38, 39] , were not different between the hypoxic rats and normoxic control before ischemia. The T 50 values were significantly increased in all groups following M I/A-R but the increases were not different among the hypoxic rats and the normoxic control.
The amplitude of electrically induced [Ca 2+ ] i transients (E[Ca 2+ ] i ) reflects the Ca 2+ release during excitationcontraction (E-C) coupling and directly correlates with shortening in rat cardiomyocytes [4, 40] . Before ischemia, the amplitude of E[Ca 2+ ] i was significantly lowered in the vehicle-treated hypoxic rats by 43.3% of the normoxic control (Fig. 6A) . The lowered E[Ca 2+ ] i level was much less in the hypoxic rats treated with melatonin, which was 20.0% of the normoxic control. The values of the amplitudes in all rat groups were significantly reduced during 1-3 min of ischemia-reperfusion with elevated ROS levels [41] . The amplitude of the E[Ca 2+ ] i in the melatonin-treated rats was significantly greater than that of vehicle group. In addition, before ischemia the decay time (T 50 ) of E[Ca 2+ ] i (Fig. 6B) which represents mainly the Ca 2+ reuptake to SR via SERCA (>90% Ca 2+ in cytoplasm) and partly the extrusion to extracellular space by NCX [42, 43] , was longer in the hypoxic rats than that of the normoxic group (by 37% and 23%, respectively, in vehicle-and melatonintreated rats). During MI/A-R, the values were markedly prolonged in the normoxic control (121% of that before MI/A-R). However, the increase in T 50 value was significantly less in the melatonin-treated rats (13% of that before MI/A-R) than that of the hypoxic rats treated with vehicle (23% of that before MI/A-R). Moreover, the time to peak of E[Ca 2+ ] i (Fig. 6C ) which indicates the speed of Ca 
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The cardiac SERCA2a expression (Fig. 7A ) was sharply decreased in the vehicle-treated hypoxic rats by 53% of the normoxic control. The reduced expression was significantly less in the hypoxic rats treated with melatonin, which was by 18.8% of the normoxic control. Yet, levels of the protein expression of Na + /Ca 2+ exchanger (NCX1) (Fig. 7B ) and ryanodine receptor (RyR2) (Fig. 7C) in CH rat hearts were not different from those of the normoxic control.
Discussion
The major finding of this study is that melatonin markedly lowered the levels of oxidative stress, [Ca 2+ ] i overload and I/R injury in the myocardium by ameliorating SERCA expression and function for the calcium handling in the SR of cardiomyocytes in CH rats. Results support the contention that antioxidant melatonin and/or its metabolites are cardioprotective against CH-induced myocardial injury.
In consistent to our previous findings [4] [5] [6] , the CH heart was hypertrophied with diminished [Ca 2+ ] i handling, which imitates the pathogenic development of heart failure. In this study, we found that melatonin treatment was significant in reducing the myocardial injury in CH rats. Hence, levels of the cardiac hypertrophy and resting LDH release were markedly lowered by melatonin treatment in the hypoxic rats. This is likely to be explained by the fact that the level of oxidative stress shown by the MDA level in the cardiac tissue of the melatonin-treated rat was not different from the normoxic control, strongly suggesting a free radical scavenging mechanism mediated by the antioxidant property of melatonin.
Previous studies have reported that melatonin is a cardioprotective agent against myocardial and I/R injuries [16] [17] [18] [19] [20] 44] . Multiple mechanisms could explain the antioxidant property of melatonin, including by scavenging oxygenbased free radicals directly [15, [45] [46] [47] [48] [49] or indirectly by stimulating antioxidant enzymes [50, 51] and increasing mitochondrial oxidative phosphorylation to lower free radical generations [45, [52] [53] [54] [55] . We found that melatonin not only reduced MDA levels, but also lowered the LDH release and infarct size induced by I/R in the CH rat heart. This observation was anticipated because melatonin treatment lessened the oxidative stress in the CH heart and this might improve cardiac tolerance against the oxidative injury induced by ROS overproduction during I/R [56] [57] [58] . These results support the idea that the administration of melatonin could be a preventive treatment for the worsening myocardial function and injury under CH conditions. Values are means ± S.E.M., n = 3-4 myocytes from three to four rats in each normoxic control, vehicle-treated (VCH) and melatonin-treated (MCH) hypoxic group. *P < 0.05, **P < 0.01 versus corresponding normoxic group; # P < 0.05 and ## P < 0.01 versus corresponding VCH group; + P < 0.05 versus corresponding group before MI/A-R.
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Yeung et al. 6   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61 For the cellular and molecular alterations in the pathogenesis of a failing heart, it is well known that Ca 2+ plays an important role in maintaining cardiac functions. The SR and sarcolemma of the cardiomyocytes are major components of normal Ca 2+ homeostasis in the heart [59] . 2+ re-uptake in the CH rat cardiomyocyte. Thus, the alterations in the SR-Ca 2+ handling and Ca 2+ homeostasis underlying the CH-induced myocardial injury were in parallel to those induced by I/R, but rather developed in a progressive manner under CH conditions. Importantly, melatonin preserved the SR-Ca 2+ content and improved contractility in the CH rat cardiomyocyte. Furthermore, the protective effect of melatonin was also effective against the additional oxidative insult imposed by MI/A-R, which are essential to the increased myocardial tolerance against I/R injury. This is in consistent with findings in previous studies suggesting that impaired myocardial and calcium handing functions are improved by the melatonin treatment [16] [17] [18] [19] [20] 67] . To address whether alterations in the expression of Ca 2+ handling proteins of SR and sarcolemma may account for the ameliorated Ca 2+ homeostasis in the CH rat cardiomyocytes, we examined the protein expression of the SERCA, RyR and NCX. Our results showed that the protein expression of SERCA, but not RyR nor NCX, was significantly attenuated in the CH rat heart, supporting that lowered SR Ca 2+ re-uptake causes the decreased SR-Ca 2+ content and impaired Ca 2+ homeostasis. This downregulation of the SERCA expression was not observed in the CH rats treated with melatonin, showing that the mechanistic effect on the ameliorated SR-Ca 2+ re-uptake and Ca 2+ homeostasis could be mediated by a transcriptional regulation of the SERCA expression. Yet, the involvement of antioxidant effect of melatonin in the mechanistic detail of the SERCA regulation awaits further investigation.
In conclusion, we have shown that melatonin was cardioprotective against CH-induced myocardial injury. Numerous other studies have also documented melatoninÕs cardioprotective actions under a variety of different situations [68] . Based on current findings, we proposed that the administration of melatonin could be a preventive approach to alleviate the oxidative stress in the heart under (A) (C) (B) Fig. 7 . Levels of the protein expression of (A) SERCA2, (B) NCX1 and (C) RyR2 in the rat heart of normoxic control, vehicle-treated (VCH) and melatonin-treated (MCH) hypoxic rats. Values are means ± S.E.M., n = 6 rats in each group. *P < 0.05 and ***P < 0.001 versus normoxic group and ### P < 0.001 versus VCH group.
CH conditions, which is a major pathogenic cause of the alterations in myocardial function leading to subsequent injury and lowered tolerance to I/R injury. The fact that chronic melatonin treatment mitigates the SR-Ca 2+ handling and Ca 2+ homeostasis in the cardiomyocyte under CH conditions, addresses the cellular mechanism for the cardioprotective effect of melatonin. In addition, the regulation of SERCA expression is involved in the mechanistic effect of melatonin on the improved myocardial function in CH, thus, functionally important for maintaining the replenishment of SR-Ca 2+ content and preventing the [Ca 2+ ] i overload. This provides a cellular basis for the better maintenance of Ca 2+ homeostasis and contractility in cardiomyocytes under CH conditions and also the tolerance to I/R-induced myocardial injuries . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61 
